Intézmény

Odette Cancer Centre

Toronto, KanadaHonlap

26futó vizsgálat
7lezárt vizsgálat
5915publikáció (OpenAlex)

Futó vizsgálatok

Toboroz
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
NCT06499285· 3. fázis· Takeda· Forrás
Toboroz
LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma
NCT06623461· 2. fázis· Canadian Cancer Trials Group· Forrás
Toboroz
Palliative Steroeotactic Body Radiotherapy vs Palliative Standard Radiotherapy in Patients With Advanced Head and Neck Cancer
NCT06641791· 3. fázis· Canadian Cancer Trials Group· Forrás
Toboroz
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes
NCT06439225· 3. fázis· Canadian Cancer Trials Group· Forrás
Fut, nem toboroz
The SOAR Study: a Study of Geriatric Assessment and Exercise for Older Adults and Their Support Person
NCT05509751· Martine Puts· Forrás
Fut, nem toboroz
A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
NCT05845814· 1/2. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
NCT05640999· 2. fázis· Canadian Cancer Trials Group· Forrás
Fut, nem toboroz
Combination of Olaparib and Navitoclax in Women with HGSC and TNBC
NCT05358639· 1. fázis· Sunnybrook Health Sciences Centre· Forrás
Fut, nem toboroz
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
NCT05217446· 2. fázis· Pfizer· Forrás
Toboroz
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
NCT04918186· 2. fázis· Canadian Cancer Trials Group· Forrás
Fut, nem toboroz
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
NCT05173987· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
NCT05116189· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
NCT04663997· 2. fázis· Canadian Cancer Trials Group· Forrás
Fut, nem toboroz
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).
NCT04895722· 2. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
NCT04586231· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
NCT04647526· 3. fázis· POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company· Forrás
Toboroz
Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer.
NCT03061435· Dr. Danielle Vicus· Forrás
Fut, nem toboroz
Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer
NCT04619069· 1/2. fázis· Sunnybrook Health Sciences Centre· Forrás
Fut, nem toboroz
Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer
NCT03784755· Canadian Cancer Trials Group· Forrás
Fut, nem toboroz
De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma
NCT03822897· 2. fázis· Canadian Cancer Trials Group· Forrás
Fut, nem toboroz
CFI-400945 in Patients With Advanced/Metastatic Breast Cancer
NCT03624543· 2. fázis· Canadian Cancer Trials Group· Forrás
Fut, nem toboroz
Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT02905318· 2. fázis· Canadian Cancer Trials Group· Forrás
Fut, nem toboroz
Phase II High Dose Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
NCT02960087· Canadian Cancer Trials Group· Forrás
Toboroz
Duration of Anti-PD-1 Therapy in Metastatic Melanoma
NCT02821013· 3. fázis· Canadian Cancer Trials Group· Forrás
Toboroz
Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer
NCT04838899· Sunnybrook Health Sciences Centre· Forrás
Fut, nem toboroz
Prostate Advances in Comparative Evidence
NCT01584258· 3. fázis· Royal Marsden NHS Foundation Trust· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

Melanóma2 toboroz
Prosztatarák2 toboroz
Fej-nyaki daganatok1 toboroz
Méhnyakrák1 toboroz
Méhtestrák1 toboroz
Mielodiszplasztikus szindróma (MDS)1 toboroz
Petefészekrák1 toboroz

Lezárt vizsgálatok

Lezárult
Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM
NCT04471844· NovoCure Ltd.· Forrás
Lezárult
Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure
NCT04442048· 3. fázis· Canadian Cancer Trials Group· Forrás
Lezárult
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
NCT03511664· 3. fázis· Endocyte· Forrás
Lezárult
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
NCT03260894· 3. fázis· Incyte Corporation· Forrás
Lezárult
Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer
NCT02788773· 2. fázis· Canadian Cancer Trials Group· Forrás
Lezárult
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
NCT02273375· 3. fázis· Canadian Cancer Trials Group· Forrás
Lezárult
Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer
NCT00819208· Canadian Cancer Trials Group· Forrás

Regiszterbeli névváltozatok (10)

A vizsgálati regiszterek ezeken a neveken tartják nyilván az intézményt. Minden sor egy regiszterbejegyzés: a címe és az alatta nyilvántartott vizsgálatok.

Odette Cancer Centre
Toronto, Ontario M4N 3M5
21 vizsgálat
Sunnybrook Research Institute, Odette Cancer Center
Toronto, Ontario M4N 3M5
3 vizsgálat
- NCT06499285A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
  Contact: Rena Buckstein (principal investigator)
- NCT04647526Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
- NCT03511664Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
Sunnybrook Health Sciences - Odette Cancer Centre
Toronto, Ontario M4N 3M5
2 vizsgálat
- NCT05217446A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
- NCT03260894Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Sunnybrook Research Institute - Odette Cancer Centre
Toronto, Ontario M4N 3M5
2 vizsgálat
- NCT05358639Combination of Olaparib and Navitoclax in Women with HGSC and TNBC
- NCT04471844Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM
Sunnybrook Health Sciences - Odette Cancer Centre (Site 0113)
Toronto, Ontario M4N 3M5
1 vizsgálat
- NCT04586231A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Sunnybrook Health Sciences - Odette Cancer Centre (Site 0508)
Toronto, Ontario M4N 3M5
1 vizsgálat
- NCT05116189Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).
Sunnybrook Health Sciences - Odette Cancer Centre (Site 0509)
Toronto, Ontario M4N 3M5
1 vizsgálat
- NCT05173987Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
Sunnybrook Research Institute - Odette Cancer Centre (Site 0316)
Toronto, Ontario M4N 3M5
1 vizsgálat
- NCT04895722Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).
Sunnybrook Research Institute - Odette Cancer Centre (Site 3108)
Toronto, Ontario M4N 3M5
1 vizsgálat
- NCT05845814A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
Sunybrook Health Sciences Centre, Odette Cancer Centre
Toronto, Ontario
1 vizsgálat
- NCT05509751The SOAR Study: a Study of Geriatric Assessment and Exercise for Older Adults and Their Support Person

Betegségek

Betegségek, amelyekről az intézmény publikál vagy amelyekre vizsgálatot futtat.

Neuroendokrin daganatok16 munka · 0 vizsgálat
Mielodiszplasztikus szindróma (MDS)8 munka · 1 vizsgálat

Intézményadatok: ROR 02ww1s787 (CC0-1.0)Frissítve: 2026. nov. 10.

Hibát jelzek